Biomarkers in individualized management of chimeric antigen receptor T cell therapy
Abstract The development of chimeric antigen receptor (CAR) T cell immunotherapy has achieved promising results, both in clinical studies and in commercial products for patients with hematologic malignancies. Despite high remission rates of CAR-T cell therapy in previously untreatable, refractory an...
Saved in:
Main Authors: | Mengyi Du (Author), Parameswaran Hari (Author), Yu Hu (Author), Heng Mei (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2020-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects
by: Zhaozhao Chen, et al.
Published: (2024) -
Chimeric antigen receptor T cell therapy for multiple myeloma
by: Kana Hasegawa, et al.
Published: (2019) -
The FDA's Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
by: Peter Marks
Published: (2019) -
Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
by: Xuejia Kang, et al.
Published: (2024) -
Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T‐Cell Therapy
by: Deni Hardiansyah, et al.
Published: (2019)